Co-administration of opioid agonists and antagonists in addiction and pain medicine

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 8, 2008, Pages 1387-1396

  Leri, Francesco ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Addiction; Naloxone; Naltrexone; Opioid; Opioid agonist; Opioid antagonist; Pain; Ultra low dose

Indexed keywords

17 METHYLNALTREXONE; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIPRURITIC AGENT; BUPRENORPHINE; CLONIDINE; FILAMIN A; METHADONE; MORPHINE; NALMEFENE; NALORPHINE; NALOXONE; NALTREXONE; NALTREXONE PLUS OXYCODONE; NARCOTIC AGENT; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OXYCODONE; OXYTREX; PENTAZOCINE; PLACEBO; SUBUXONE; TALWIN NX; TILIDINE; VALORON N; MU OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ACUTE CONFUSION; ANALGESIA; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DELIRIUM; DEPRESSION; DETOXIFICATION; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG DEPENDENCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUPHORIA; FIRST PASS EFFECT; FLUSHING; GENERAL ANESTHESIA; HUMAN; ILEUS; INTOXICATION; LOW BACK PAIN; LOW DRUG DOSE; MONOTHERAPY; MOOD CHANGE; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; POSTOPERATIVE PAIN; PRURITUS; QUALITY OF LIFE; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; REVIEW; RISK REDUCTION; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH SECRETION; SYMPTOMATOLOGY; THERAPY EFFECT; VOMITING; WITHDRAWAL SYNDROME; DRUG ADMINISTRATION ROUTE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; OPIATE ADDICTION;

ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG THERAPY, COMBINATION; HUMANS; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN; RECEPTORS, OPIOID, MU;

EID: 45549086362     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.8.1387     Document Type: Review

References (145)

1. Flugsrud-Breckenridge MR, Gevirtz C, Paul D, Gould HJ III. Medications of abuse in pain management. Curr Opin Anaesthesiol 2007;20:319-24
2. Manchikanti L. National drug control policy and prescription drug abuse; facts and fallacies. Pain Physician 2007;10:399-424
3. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007;129:235-55
4. Carise D, Dugosh KL, McLellan AT, et al. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 2007;164:1750-6
5. Comer SD, Sullivan MA, Whittington RA, et al. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 2008;33(5):1179-91
6. Gustein HB, Akil H. Opioid analgesics. In: Hardman JG, Limbird LE, editors, Goodman & Gilman's: The pharmacological basis of therapeutics. 10th edition. New York: McGraw-Hill; 2001. p. 569-619
7. Foldes FF, Lunn JN, Moore J, Brown IM. N-allylnoroxy-morphone: a new potent narcotic antagonist. Am J Med Sci 1963;245:23-30
8. Handal KA, Schauben JL, Salamone FR. Naloxone. Ann Emerg Med 1983;12:438-45
9. Berkowitz BA, Ngai SH, Hempstead J, Spector S. Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther 1975;195:499-504
10. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet 1976;1:219-30
11. Fishman J, Roffwarg H, Hellman L. Disposition of naloxone-7,8,3H in normal and narcotic-dependent men. J Pharmacol Exp Ther 1973;187:575-80
12. Preston KL, Bigelow GE, Liebson IA. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend 1990;25:27-34
13. Sporer KA. Acute heroin overdose. Ann Intern Med 1999;130:584-90
14. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 1973;28:784-91
15. O'Brien CP, Greenstein R, Ternes J, Woody GE. Clinical pharmacology of narcotic antagonists. Ann NY Acad Sci 1978;311:232-40
16. Cone EJ, Gorodetzky CW, Yeh SY. The urinary excretion profile of naltrexone and metabolites in man. Drug Metab Dispos 1974;2:506-12
17. Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 1976;20:315-28
18. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Goodman and Gilman's the pharmacological basis of therapeutics. 7th edition. New York: McMillan; 1985. p. 485-521
19. Kosterlitz HW, Leslie FM. Comparison of the receptor binding characteristics of opiate agonists interacting with mu- or kappa-receptors. Br J Pharmacol 1978;64:607-14
20. Berkowitz BA. The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet 1976;1:219-30
21. Jasinski DR, Martin WR, Haertzen CA. The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther 1967;157:420-6
22. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000;133:40-54
23. McClung CA. The molecular mechanisms of morphine addiction. Rev Neurosci 2006;17:393-402
24. Watts VJ. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J Pharmacol Exp Ther 2002;302:1-7
25. Van Bockstaele EJ, Menko AS, Drolet G. Neuroadaptive responses in brainstem noradrenergic nuclei following chronic morphine exposure. Mol Neurobiol 2001;23:155-71
26. Contarino A, Papaleo F. The corticotropin-releasing factor receptor-1 pathway mediates the negative affective states of opiate withdrawal. Proc Natl Acad Sci USA 2005;102:18649-54
27. Iredale PA, Alvaro JD, Lee Y, et al. Role of corticotropin-releasing factor receptor-1 in opiate withdrawal. J Neurochem 2000;74:199-208
28. Schluger JH, Bart G, Green M, et al. Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained vs control subjects. Neuropsychopharmacology 2003;28:985-94
29. Paul D, Pick CG, Tive LA, Pasternak GW. Pharmacological characterization of nalorphine, a kappa 3 analgesic. J Pharmacol Exp Ther 1991;257:1-7
30. Hoskin PJ, Hanks GW. Opioid agonist-antagonist drugs in acute and chronic pain states. Drugs 1991;41:326-44
31. Wikler A, Fraser HF, Isbell H. N-Allylnormorphine: effects of single doses and precipitation of acute abstinence syndromes during addiction to morphine; methadone or heroin in man (post addicts). J Pharmacol Exp Ther 1953;109:8-20
32. Wang RI, Wiesen RL, Lamid S, Roh BL. Rating the presence and severity of opiate dependence. Clin Pharmacol Ther 1974;16:653-8
33. Blachly PH. Naloxone for diagnosis in methadone programs. JAMA 1973;224:334-5
34. Sutherland G, Edwards G, Taylor C, et al. The measurement of opiate dependence. Br J Addict 1986;81:485-94
35. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. Res Publ Assoc Res Nerv Ment Dis 1992;70:205-30
36. Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict 2003; 12(Suppl 2):S5-18
37. Singh J, Basu D. Ultra-rapid opioid detoxification: current status and controversies. J Postgrad Med 2004;50:227-32
38. Streel E, Verbanck P. Ultra-rapid opiate detoxification: from clinical applications to basic science. Addict Biol 2003;8:141-6
39. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA 1998;279:229-34
40. Meyer RE, Mirin SM. The heroin stimulus, implications for a theory of addiction. New York: Plenum Publishing Corporation; 1979
41. Meyer RE, Mirin SM, Altman JL, McNamee HB. A behavioral paradigm for the evaluation of narcotic antagonists. Arch Gen Psychiatry 1976;33:371-7
42. Hammond AL. Narcotic antagonists: new methods to treat heroin addiction. Science 1971;173:503-6
43. Wikler A. Dynamics of drug dependence. Implications of a conditioning theory for research and treatment. Arch Gen Psychiatry 1973;28:611-6
44. O'Brien CP, Childress AR, McLellan AT, et al. Use of naltrexone to extinguish opioid-conditioned responses. J Clin Psychiatry 1984;45:53-6
45. Kleber HD. Naltrexone. J Subst Abuse Treat 1985;2:117-22
46. Caruso FS, Gordon M, Pachter IJ. Methadone and naloxone in combination (naldone) for the treatment of heroin addicts. Proc Natl Conf Methadone Treat 1973;2:1336-41
47. Loimer N, Presslich O, Grunberger J, Linzmayer L. Combined naloxone/ methadone preparations for opiate substitution therapy. J Subst Abuse Treat 1991;8:157-60
48. Nutt JG, Jasinski DR. Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility. II. Demonstration of acute physical dependence. Clin Pharmacol Ther 1974;15:156-66
49. Parwatikar SD, Knowles RR. Methadone-naloxone in combination for the treatment of heroin addicts. Clin Pharmacol Ther 1973;14:941-8
50. Legros J, Khalili-Varasteh H, Margetts G. Pharmacological study of pentazocine-naloxone combination: interest as a potentially non abusable oral form of pentazocine. Arch Int Pharmacodyn Ther 1984;271:11-21
51. True WR, Poklis A, Jamieson RW, Seyfried W. Pentazocine-naloxone experimenters among abusers of pentazocine and tripelennamine from a VA treatment population. Int J Addict 1988;23:217-26
52. Hogger P, Rohdewald P. Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers. Int J Clin Pharmacol Ther 1999;37:377-85
53. Van CH, Rubwiedel M, Albert A, Franchimont P. Comparative study of tilidine-naloxone and pentazocine in knee and hip osteoarthritis. Int J Clin Pharmacol Res 1992;12:1-9
54. Fudala PJ, Johnson RE. Development of opioid formulations with limited diversion and abuse potential. Drug Alcohol Depend 2006;83(Suppl 1):S40-47
55. Kanof PD, Handelsman L, Aronson MJ, et al. Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J Pharmacol Exp Ther 1992;260:355-63
56. Fudala PJ, Woody GW. Recent advances in the treatment of opiate addiction. Curr Psychiatry Rep 2004;6:339-46
57. Strang J. Abuse of buprenorphine. Lancet 1985;2:725
58. Robinson GM, Dukes PD, Robinson BJ, et al. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993;33:81-6
59. Strain EC, Walsh SL, Preston KL, et al. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology 1997;129:329-38
60. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment? Drug Alcohol Depend 2003;70:S29-37
61. Bell J, Byron G, Gibson A, Morris A. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 2004;23:311-7
62. Rapeli P, Fabritius C, Alho H, et al. Methadone vs. buprenorphine/ naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 2007;7:5
63. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment. including buprenorphine/naloxone. Ann Pharmacother 2002;36:312-21
64. Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep 2000;2:519-26
65. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005;162:1432-40
66. Chawarski MC, Schottenfeld RS, O'Connor PG, Pakes J. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend 1999;55:157-63
67. Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 2005;181:664-75
68. Comer SD, Collins ED. Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. J Pharmacol Exp Ther 2002;303:695-703
69. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88:75-8
70. McNicol E, Horowicz-Mehler N, Fisk RA, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain 2003;4:231-56
71. Friedman JD, Io Buono FA. Opioid antagonists in the treatment of opioid-induced constipation and pruritus. Ann Pharmacother 2001;35:85-91
72. Sykes NP. Oral naloxone in opioid-associated constipation. Lancet 1991;337:1475
73. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53
74. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992;52:90-5
75. Sykes NP. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 1996;10:135-44
76. Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain 2000;84:105-9
77. Patch GG, Morton KA, Arias JM, Datz FL. Naloxone reverses pattern of obstruction of the distal common bile duct induced by analgesic narcotics in hepatobiliary imaging. J Nucl Med 1991;32:1270-2
78. Butler KC, Selden B, Pollack CV Jr. Relief by naloxone of morphine-induced spasm of the sphincter of Oddi in a post-cholecystectomy patient. J Emerg Med 2001;21:129-31
79. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 2007;10:357-66
80. Abboud TK, Lee K, Zhu J, et al. Prophylactic oral naltrexone with intrathecal morphine for cesarean section: effects on adverse reactions and analgesia. Anesth Analg 1990;71:367-70
81. Goodman AJ, Le BB, Dolle RE. Mu opioid receptor antagonists: recent developments. Chem Med Chem 2007;2:1552-70
82. Shaiova L, Rim F, Friedman D, Jahdi M. A review of methylnaltrexone, a peripheral opioid receptor antagonist, and its role in opioid-induced constipation. Palliat Support Care 2007;5:161-6
83. Russell J, Bass P, Goldberg LI, et al. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 1982;78:255-61
84. Brown DR, Goldberg LI. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985;24:181-91
85. Murphy DB, Sutton JA, Prescott LF, Murphy MB. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 1997;87:765-70
86. Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000;283:367-72
87. Yuan CS, Foss JF, O'Connor M, et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 1998;52:161-5
88. Yuan CS, Wei G, Foss JF, et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 2002;300:118-23
89. Gupta PK, Dundee JW. Morphine combined with doxapram or naloxone. A study of post-operative pain relief. Anaesthesia 1974;29:33-9
90. Gairola RL, Gupta PK, Pandley K. Antagonists of morphine-induced respiratory depression. A study in postoperative patients. Anaesthesia 1980;35:17-21
91. Crain SM, Shen KF. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/ dependence during chronic cotreatment. Proc Natl Acad Sci USA 1995;92:10540-4
92. Powell KJ, Abul-Husn NS, Jhamandas A, et al. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 2002;300:588-96
93. Shen KF, Crain SM, Moate P, et al. PTI-801, a novel formulation of oxycodone, shows absence of tolerance, physical dependence and naloxone-precipitated withdrawal effects in mice. Pain 2002;3:49
94. Shen KF, Crain SM. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res 1997;757:176-90
95. Crain SM, Shen KF. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/ dependence liability. Pain 2000;84:121-31
96. Webster LR. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 2007;16:1277-83
97. Crain SM, Shen KF. Modulation of opioid analgesia, tolerance and dependence by Gs-coupled, GM1 ganglioside-regulated opioid receptor functions. Trends Pharmacol Sci 1998;19:358-65
98. Wang HY, Friedman E, Burns LH. Ultra-low-dose naloxone attenuates chronic morphine-induced changes in Mu opioid receptor - G protein coupling and Gβγ signaling. Neuroscience 2005;135:247-61
99. Wang HY, Burns LH. Gbetagamma that interacts with adenylyl cyclase in opioid tolerance originates from a Gs protein. J Neurobiol 2006;66:1302-10
100. Wang HY, Frankfurt M, Burns LH. High-affinity naloxone binding to filamin a prevents mu opioid receptor-gs coupling underlying opioid tolerance and dependence. PLoS One 2008;3:e1554
101. Onoprishvili I, Andria ML, Kramer HK, et al. Interaction between the mu opioid receptor and filamin A is involved in receptor regulation and trafficking. Mol Pharmacol 2003;64:1092-100
102. Gharagozlou P, Demirci H, David CJ, Lameh J. Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol 2003;3:1
103. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 1994;271:1630-7
104. Joshi GP, Duffy P, Chehade J, et al. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 1999;90:1007-11
105. Cruciani RA, Lussier D, Miller-Saultz D, Arbuck DM. Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone. J Pain Symptom Manage 2003;25:491-4
106. Hamann S, Sloan P. Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study. J Opioid Manag 2007;3:137-44
107. Chindalore VL, Craven RA, Yu KP, et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005;6:392-9
108. Webster LR, Butera PG, Moran LV, et al. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006;7:937-46
109. Charney DS, Redmond DE Jr, Galloway MP, et al. Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity. Life Sci 1984;35:1263-72
110. Haertzen CA, Meketon MJ, Hooks NT Jr. Subjective experiences produced by the withdrawal of opiates. Br J Addict Alcohol Other Drugs 1970;65:245-55
111. Preston KL, Bigelow GE, Liebson IA. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther 1989;248:929-37
112. Sutherland G, Edwards G, Taylor C, et al. The opiate dependence syndrome: replication study using the SODQ in a New York clinic. Br J Addict 1988;83:755-60
113. Sullivan MA, Garawi F, Bisaga A, et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007;91:289-92
114. Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 2006;189:37-46
115. Kirchmayer U, Davoli M, Verster AD, et al. A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 2002;97:1241-9
116. Fram DH, Marmo J, Holden R. Naltrexone treatment - the problem of patient acceptance. J Subst Abuse Treat 1989;6:119-22
117. Stitzer M, Petry N. Contingency management for treatment of substance abuse. Ann Rev Clin Psychol 2006;2:411-34
118. Carroll KM, Sinha R, Nich C, et al. Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. Exp Clin Psychopharmacol 2002;10:54-63
119. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction 2006;101:491-503
120. Tucker T, Ritter A, Maher C, Jackson H. Naltrexone maintenance for heroin dependence: uptake, attrition and retention. Drug Alcohol Rev 2004;23:299-309
121. Dijkstra BA, De Jong CA, Bluschke SM, et al. Does naltrexone affect craving in abstinent opioid-dependent patients? Addict Biol 2007;12:176-82
122. Kruptisky EM, Burakov AM, Tsoy MV, et al. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction 2007;102:1164-5
123. Ritter AJ. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Aust N Z J Psychiatry 2002;36:224-8
124. Byrne A, Graham C, Hallinan R, Murnion B. Naltrexone implants as treatment for heroin dependence: part I. Addict Biol 2005;10:201-2
125. Wodak A, Graham R. Naltrexone implants as treatment for heroin dependence: part II. Addict Biol 2005;10:202-4
126. Janson W, Stein C. Peripheral opioid analgesia. Curr Pharm Biotechnol 2003;4:270-4
127. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995;332:1685-90
128. Schafer M, Imai Y, Uhl GR, Stein C. Inflammation enhances peripheral mu-opioid receptor-mediated analgesia, but not mu-opioid receptor transcription in dorsal root ganglia. Eur J Pharmacol 1995;279:165-9
129. Stein C, Hassan AH, Przewlocki R, et al. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci USA 1990;87:5935-9
130. Stein C, Hassan AH, Lehrberger K, et al. Local analgesic effect of endogenous opioid peptides. Lancet 1993;342:321-4
131. Przewlocki R, Hassan AH, Lason W, et al. Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. Neuroscience 1992;48:491-500
132. Carr DJ. The role of endogenous opioids and their receptors in the immune system. Proc Soc Exp Biol Med 1991;198:710-20
133. Sharp B, Linner K. What do we know about the expression of proopiomelanocortin transcripts and related peptides in lymphoid tissue? Endocrinology 1993;133:1921A-1921B
134. Rogers H, Birch PJ, Harrison SM, et al. GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity. Br J Pharmacol 1992;106:783-9
135. Giardina G, Clarke GD, Grugni M, et al. Central and peripheral analgesic agents: chemical strategies for limiting brain penetration in kappa-opioid agonists belonging to different chemical classes. Farmaco 1995;50:405-18
136. Cepeda MS, Africano JM, Manrique AM, et al. The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain 2002;96:73-9
137. Mehlisch DR. The combination of low dose of naloxone and morphine in patient-controlled (PCA) does not decrease opioid requirements in the postoperative period. Pain 2003;101:209-11
138. Cepeda MS, Alvarez H, Morales O, Carr DB. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004;107:41-6
139. Bijur PE, Schechter C, Esses D, et al. Intravenous bolus of ultra-low-dose naloxone added to morphine does not enhance analgesia in emergency department patients. J Pain 2006;7:75-81
140. Sartain JB, Barry JJ, Richardson CA, Branagan HC. Effect of combining naloxone and morphine for intravenous patient-controlled analgesia. Anesthesiology 2003;99:148-51
141. Galeotti N, Stefano GB, Guarna M, et al. Signaling pathway of morphine induced acute thermal hyperalgesia in mice. Pain 2006;123:294-305
142. Shen KF, Crain SM. Cholera toxin-B subunit blocks excitatory apioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence. Brain Res 2001;919:20-30
143. Crain SM, Shen KF, Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia. Brain Res 2001;888:75-82
144. Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology 2005;181:576-81
145. Leri F, Burns LH. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 2005;82:252-62